Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management

Evelyn S. Marienberg, MD


November 08, 2022

According to the AUA, a patient with metastatic CRPC who has a poor performance status and has not been treated with docetaxel should be treated with an androgen synthesis inhibitor plus glucocorticoid or androgen receptor inhibitor. An immunotherapeutic agent, like sipuleucel-T, should not be offered. Monotherapy with a taxane, like docetaxel, is not recommended, but it can be combined with androgen synthesis inhibitor. Watchful waiting is recommended by the AUA for patients with low-risk or intermediate-risk localized prostate cancer and a life expectancy ≤ 5 years.

Learn more about the management of metastatic CRPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.